Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CLEC4C


Brief Information

Name:C-Type lectin domain family 4 member C
Target Synonym:DLEC,HECL,C-type lectin superfamily member 7,CLEC4C,BDCA2,UNQ9361/PRO34150,C-type lectin domain family 4 member C,Dendritic lectin,C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 7,C-Type Lectin Domain Family 4, Member C,CLECSF11,CLECSF7,BDCA-2,C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 11,Blood Dendritic Cell Antigen 2 Protein,Blood Dendritic Cell Antigen 2,Dendritic Cell Lectin B,CD303 Antigen,PRO34150,CD303
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CLC-H5245 Human Human CLEC4C / BDCA2 Protein, His Tag
CLC-C52H4 Cynomolgus Cynomolgus CLEC4C / BDCA2 Protein, His Tag (MALS verified)
CLC-H5254 Human Human CLEC4C / BDCA2 Protein, Fc Tag
ACRO Quality

Part of Bioactivity data

The purity of Cynomolgus CLEC4C, His Tag (Cat. No. CLC-C52H4) is more than 90% and the molecular weight of this protein is around 59-80 kDa verified by SEC-MALS.

Synonym Name



CLEC4C (C-type lectin domain family 4 member C), also known as BDCA2, CLECSF11, CLECSF7, DLEC and CD303. Lectin-type cell surface receptor which may play a role in antigen capturing by dendritic cell. Specifically recognizes non-sialylated galactose-terminated biantennary glycans containing the trisaccharide epitope Gal(beta1-3/4)GlcNAc(beta1-2)Man. Binds to serum IgG. Efficiently targets ligand into antigen-processing and peptide-loading compartments for presentation to T-cells. May mediate potent inhibition of induction of IFN-alpha/beta expression in plasmacytoid dendritic cells. May act as a signaling receptor that activates protein-tyrosine kinases and mobilizes intracellular calcium.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Litifilimab BIIB-059 Phase 3 Clinical Biogen Inc Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message